140 related articles for article (PubMed ID: 29243388)
21. A pseudo-random patient sampling method evaluated.
De La Mata NL; Ahn MY; Kumarasamy N; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Durier N; Law MG
J Clin Epidemiol; 2017 Jan; 81():129-139. PubMed ID: 27771357
[TBL] [Abstract][Full Text] [Related]
22. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
23. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
25. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
[TBL] [Abstract][Full Text] [Related]
26. Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).
Martinez-Vega R; De La Mata NL; Kumarasamy N; Ly PS; Van Nguyen K; Merati TP; Pham TT; Lee MP; Choi JY; Ross JL; Ng OT
Antivir Ther; 2018; 23(2):167-178. PubMed ID: 28933705
[TBL] [Abstract][Full Text] [Related]
27. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
Charpentier C; Peytavin G; Lê MP; Joly V; Cabras O; Perrier M; Le Gac S; Phung B; Yazdanpanah Y; Descamps D; Landman R
J Antimicrob Chemother; 2018 Jun; 73(6):1665-1671. PubMed ID: 29528412
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Rusconi S; Caramello P; Abrescia N; Mussini C; Monno L; d'Arminio Monforte A;
Clin Microbiol Infect; 2016 Mar; 22(3):288.e1-8. PubMed ID: 26551839
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
30. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)?
Saunders P; Goodman AL; Smith CJ; Marshall N; O'Connor JL; Lampe FC; Johnson MA
HIV Med; 2016 Jan; 17(1):18-27. PubMed ID: 26140659
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys EH; Chang LW; Harris J
Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
[TBL] [Abstract][Full Text] [Related]
32. The TREAT Asia HIV Observational Database: baseline and retrospective data.
Zhou J; Kumarasamy N; Ditangco R; Kamarulzaman A; Lee CK; Li PC; Paton NI; Phanuphak P; Pujari S; Vibhagool A; Wong WW; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG;
J Acquir Immune Defic Syndr; 2005 Feb; 38(2):174-9. PubMed ID: 15671802
[TBL] [Abstract][Full Text] [Related]
33. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
34. Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.
Jiamsakul A; Kerr SJ; Ng OT; Lee MP; Chaiwarith R; Yunihastuti E; Van Nguyen K; Pham TT; Kiertiburanakul S; Ditangco R; Saphonn V; Sim BL; Merati TP; Wong W; Kantipong P; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Oka S; Mustafa M; Ratanasuwan W; Petersen B; Law M; Kumarasamy N;
Trop Med Int Health; 2016 May; 21(5):662-74. PubMed ID: 26950901
[TBL] [Abstract][Full Text] [Related]
35. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015.
Kyaw NT; Harries AD; Kumar AM; Oo MM; Kyaw KW; Win T; Aung TK; Min AC; Oo HN
PLoS One; 2017; 12(2):e0171780. PubMed ID: 28182786
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral treatment failure predicts mortality in rural Tanzania.
Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
[TBL] [Abstract][Full Text] [Related]
37. Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region.
Wright S; Boyd MA; Yunihastuti E; Law M; Sirisanthana T; Hoy J; Pujari S; Lee MP; Petoumenos K;
PLoS One; 2013; 8(6):e64902. PubMed ID: 23840312
[TBL] [Abstract][Full Text] [Related]
38. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
39. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
[TBL] [Abstract][Full Text] [Related]
40. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
